The FDA pause on Regenxbio should rattle every AAV gene therapy company
Regenxbio's latest trial hold isn't isolated — five spinal masses in Hunter syndrome patients add to a growing pattern that could slow AAV gene therapies across the board. The FDA's scrutiny is intensifying.